Skip to main content

Advertisement

Springer Nature Link
Log in

The analysis of CIS, SOCS1, SOSC2 and SOCS3 transcript levels in peripheral blood mononuclear cells of systemic lupus erythematosus and rheumatoid arthritis patients

  • Original Article
  • Published:
Clinical and Experimental Medicine Aims and scope Submit manuscript

Abstract

Being expressed in immune cells, cytokine-inducible SH2 protein (CIS) and suppressors of cytokine signaling proteins, SOCS1, SOCS2 and SOCS3, can regulate cytokine signaling and immune responses. To evaluate the possible expressional dysregulation of CIS, SOCS1, SOCS2 and SOCS3 in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients, the transcript levels of these genes in peripheral blood mononuclear cells (PBMCs) from SLE and RA patients were determined and statistically compared with those in PBMCs from normal individuals. It was found that SLE patients with the active disease activity significantly express higher CIS transcript levels than normal individuals and SLE patients with the inactive disease activity, whereas the difference in SOCS1, SOCS2 and SOCS3 transcript levels between normal individuals and SLE patients is not statistically significant. However, transcript levels of these CIS/SOCS genes in RA patients were not significantly different from those in normal individuals, except that treatment with a TNF-α-blocking agent in RA patients appears to enhance the CIS transcript expression, but down-regulates the SOCS2 transcript expression in PBMCs. These data suggest that CIS can serve as an SLE disease marker and may be involved in the pathogenesis of SLE, and that TNF-α may play an important role in the regulation of CIS and SOCS2 gene expression in PBMCs in vivo.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Canada)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Rakesh K, Agrawal DK (2005) Controlling cytokine signaling by constitutive inhibitors. Biochem Pharmacol 70:649–657

    Article  PubMed  CAS  Google Scholar 

  2. Fujimoto M, Naka T (2003) Regulation of cytokine signaling by SOCS family molecules. Trends Immunol 24:659–666

    Article  PubMed  CAS  Google Scholar 

  3. Alexander WS, Hilton DJ (2004) The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu Rev Immunol 22:503–529

    Article  PubMed  CAS  Google Scholar 

  4. Yoshimura A, Naka T, Kubo M (2007) SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol 7:454–465

    Article  PubMed  CAS  Google Scholar 

  5. Li S, Chen S, Xu X et al (2000) Cytokine-induced Src homology 2 protein (CIS) promotes T cell receptor-mediated proliferation and prolongs survival of activated T cells. J Exp Med 191:985–994

    Article  PubMed  CAS  Google Scholar 

  6. Matsumoto A, Seki Y, Kubo M et al (1999) Suppression of STAT5 functions in liver, mammary glands, and T cells in cytokine-inducible SH2-containing protein 1 transgenic mice. Mol Cell Biol 19:6396–6407

    PubMed  CAS  Google Scholar 

  7. Naka T, Matsumoto T, Narazaki M et al (1998) Accelerated apoptosis of lymphocytes by augmented induction of Bax in SSI-1 (STAT-induced STAT inhibitor-1) deficient mice. Proc Natl Acad Sci USA 95:15577–15582

    Article  PubMed  CAS  Google Scholar 

  8. Starr R, Metcalf D, Elefanty AG et al (1998) Liver degeneration and lymphoid deficiencies in mice lacking suppressor of cytokine signaling-1. Proc Natl Acad Sci USA 95:14395–14399

    Article  PubMed  CAS  Google Scholar 

  9. Alexander WS, Starr R, Fenner JE et al (1999) SOCS1 is a critical inhibitor of interferon γ signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell 98:597–608

    Article  PubMed  CAS  Google Scholar 

  10. Marine J-C, Topham DJ, McKay C et al (1999) SOCS1 deficiency causes a lymphocyte-dependent perinatal lethality. Cell 98:609–616

    Article  PubMed  CAS  Google Scholar 

  11. Kinjyo I, Hanada T, Inagaki-Ohara K et al (2002) SOCS1/JAB is a negative regulator of LPS-induced macrophage activation. Immunity 17:583–591

    Article  PubMed  CAS  Google Scholar 

  12. Nakagawa R, Naka T, Tsutsui H et al (2002) SOCS-1 participates in negative regulation of LPS responses. Immunity 17:677–687

    Article  PubMed  CAS  Google Scholar 

  13. Hanada T, Yoshida H, Kato S et al (2003) Suppressor of cytokine signaling-1 is essential for suppressing dendritic cell activation and systemic autoimmunity. Immunity 19:437–450

    Article  PubMed  CAS  Google Scholar 

  14. Catlett IM, Hedrick SM (2005) Suppressor of cytokine signaling 1 is required for the differentiation of CD4+ T cells. Nat Immunol 6:715–721

    Article  PubMed  CAS  Google Scholar 

  15. Metcalf D, Greenhalgh CJ, Viney E et al (2000) Gigantism in mice lacking suppressor of cytokine signalling-2. Nature 405:1069–1073

    Article  PubMed  CAS  Google Scholar 

  16. Greenhalgh CJ, Rico-Bautista E, Lorentzon M et al (2005) SOCS2 negatively regulates growth hormone action in vitro and in vivo. J Clin Invest 115:397–406

    PubMed  CAS  Google Scholar 

  17. Rico-Bautista E, Flores-Morales A, Fernández-Pérez L (2006) Suppressor of cytokine signaling (SOCS) 2, a protein with multiple functions. Cytokine Growth Factor Rev 17:431–439

    Article  PubMed  CAS  Google Scholar 

  18. Machado FS, Johndrow JE, Esper L et al (2006) Anti-inflammatory actions of lipoxin A4 and aspirin-triggered lipoxin are SOCS-2 dependent. Nat Med 12:330–334

    Article  PubMed  CAS  Google Scholar 

  19. Cohney SJ, Sanden D, Cacalano NA et al (1999) SOCS-3 is tyrosine phosphorylated in response to interleukin-2 and suppresses STAT5 phosphorylation and lymphocyte proliferation. Mol Cell Biol 19:4980–4988

    PubMed  CAS  Google Scholar 

  20. Suzuki A, Hanada T, Mitsuyama K et al (2001) CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation. J Exp Med 193:471–481

    Article  PubMed  CAS  Google Scholar 

  21. Seki Y, Inoue H, Nagata N et al (2003) SOCS-3 regulates onset and maintenance of TH2-mediated allergic responses. Nat Med 9:1047–1054

    Article  PubMed  CAS  Google Scholar 

  22. Yasukawa H, Ohishi M, Mori H et al (2003) IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat Immunol 4:551–556

    Article  PubMed  CAS  Google Scholar 

  23. Takatori H, Nakajima H, Kagami S et al (2005) Stat5a inhibits IL-12-induced Th1 cell differentiation through the induction of suppressor of cytokine signaling 3 expression. J Immunol 174:4105–4112

    PubMed  CAS  Google Scholar 

  24. Chen Z, Laurence A, Kanno Y et al (2006) Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. Proc Natl Acad Sci USA 103:8137–8142

    Article  PubMed  CAS  Google Scholar 

  25. Oberg HH, Wesch D, Grüssel S, Rose-John S, Kabelitz D (2006) Differential expression of CD126 and CD130 mediates different STAT-3 phosphorylation in CD4+CD25- and CD25high regulatory T cells. Int Immunol 18:555–563

    Article  PubMed  CAS  Google Scholar 

  26. Llorente L, Richaud-Patin Y, García-Padilla C et al (2000) Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 43:1790–1800

    Article  PubMed  CAS  Google Scholar 

  27. Feldmann M, Maini R (2001) Anti-TNFα therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 19:163–196

    Article  PubMed  CAS  Google Scholar 

  28. Lauwerys BR, Houssiau FA (2003) Involvement of cytokines in the pathogenesis of systemic lupus erythematosus. Adv Exp Med Biol 520:237–251

    PubMed  CAS  Google Scholar 

  29. Miossec P (2004) An update on the cytokine network in rheumatoid arthritis. Curr Opin Rheumatol 16:218–222

    Article  PubMed  CAS  Google Scholar 

  30. Banchereau J, Pascual V (2006) Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 25:383–392

    Article  PubMed  CAS  Google Scholar 

  31. Tan EM, Cohen AS, Fries JF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277

    Article  PubMed  CAS  Google Scholar 

  32. Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324

    Article  PubMed  CAS  Google Scholar 

  33. Bombardier C, Gladman D, Urowitz M, Caron D, Chang C (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35:630–640

    Article  PubMed  CAS  Google Scholar 

  34. Fujimoto M, Tsutsui H, Xinshou O et al (2004) Inadequate induction of suppressor of cytokine signaling-1 causes systemic autoimmune diseases. Int Immunol 16:303–314

    Article  PubMed  CAS  Google Scholar 

  35. Llorente L, Zou W, Levy Y et al (1995) Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 181:839–844

    Article  PubMed  CAS  Google Scholar 

  36. Lacki JK, Leszczynski P, Kelemen J, Müller W, Mackiewicz SH (1997) Cytokine concentration in serum of lupus erythematosus patients: the effect on acute phase response. J Med 28:99–107

    PubMed  CAS  Google Scholar 

  37. Shen X, Hong F, Nguyen VA, Gao B (2000) IL-10 attenuates IFN-α-activated STAT1 in the liver: involvement of SOCS2 and SOCS3. FEBS Lett 480:132–136

    Article  PubMed  CAS  Google Scholar 

  38. Egan PJ, Lawlor KE, Alexander WS, Wicks IP (2003) Suppressor of cytokine signaling-1 regulates acute inflammatory arthritis and T cell activation. J Clin Invest 111:915–924

    PubMed  CAS  Google Scholar 

  39. Wong PK, Egan PJ (2006) Croker BA et al (2006) SOCS-3 negatively regulates innate and adaptive immune mechanisms in acute IL-1-dependent inflammatory arthritis. J Clin Invest 116:1571–1581

    Article  PubMed  CAS  Google Scholar 

  40. Shouda T, Yoshida T, Hanada T et al (2001) Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis. J Clin Invest 108:1781–1788

    PubMed  CAS  Google Scholar 

  41. Shou J, Bull CM, Li L et al (2006) Identification of blood biomarkers of rheumatoid arthritis by transcript profiling of peripheral blood mononuclear cells from the rat collagen-induced arthritis model. Arthritis Res Ther 8:R28

    Article  PubMed  Google Scholar 

  42. Isomäki P, Alanärä T, Isohanni P et al (2007) The expression of SOCS is altered in rheumatoid arthritis. Rheumatology 46:1538–1546

    Article  PubMed  Google Scholar 

  43. Charles PJ, Smeenk RJT, De Jong J, Feldmann M, Maini RN (2000) Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 43:2383–2390

    Article  PubMed  CAS  Google Scholar 

  44. Shakoor N, Michalska M, Harris CA, Block JA (2002) Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 359:645

    Article  Google Scholar 

  45. De Bandt M, Sibilia J, Le Loët X et al (2005) Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 7:R545–R551

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

I thank Yanfeng Lu for review of the manuscript. This project is supported by a joined grant from Cathay General Hospital and Taipei Medical University (Grant# 94CGH-TMU-07).

Conflict of interest statement

The authors declare that they have no conflict of interest related to the publication of this manuscript.

Author information

Authors and Affiliations

  1. Division of Allergy and Immunology, Department of Internal Medicine, Cathay General Hospital, Taipei, Taiwan, ROC

    Jeng-Ting Tsao, Chia-Chen Kuo & Shih-Chang Lin

  2. The Laboratory of Allergy and Immunology, Cathay Medical Research Institute, Hsichih Shien, Taipei Shien, Taiwan, ROC

    Shih-Chang Lin

  3. Department of Medicine, School of Medicine, Fu Jen Catholic University, Hsinchuang, Taipei Shien, Taiwan, ROC

    Shih-Chang Lin

Authors
  1. Jeng-Ting Tsao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chia-Chen Kuo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shih-Chang Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shih-Chang Lin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tsao, JT., Kuo, CC. & Lin, SC. The analysis of CIS, SOCS1, SOSC2 and SOCS3 transcript levels in peripheral blood mononuclear cells of systemic lupus erythematosus and rheumatoid arthritis patients. Clin Exp Med 8, 179–185 (2008). https://doi.org/10.1007/s10238-008-0006-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10238-008-0006-0

Keywords

Search

Navigation